Proteintech launches New Multi-rAb Recombinant Secondary Antibodies

17 October 2023 | Tuesday | News

This New Generation of Secondary Antibodies has superior sensitivity, high reproducibility
Image Source | Public Domain

Image Source | Public Domain

Proteintech, a global leader in antibodies, immunoassay kits, and recombinant proteins,announced the launch of Multi-rAb Recombinant Secondary Antibodies, the newest generation of secondary antibodies designed to deliver unparallel specificity and reproducibility in widely used immunoassays.

Secondary antibodies are one of the most widely used reagents, making them indispensable tools for biomedical research. While most researchers rely on traditional polyclonal secondary antibodies, they face several challenges of high cross reactivity leading to high background and non-specific signals or they have to buy expensive highly cross adsorbed, less sensitive antibodies to avoid cross reactivity.

“Our new Multi-rAb secondary antibodies are designed to address this specific issue. The Multi-rAbs are a finely crafted clonal mix of recombinant monoclonal antibodies that have been characterized to have better sensitivity, minimal cross reactivity and high reproducibility,” says Dr. Deepa Shankar, Proteintech’s Chief Scientific Officer.

Researchers will be able to achieve the same enhanced levels of species specificity and reduced background with Multi-rAb secondaries as with highly cross-adsorbed traditional secondaries while maintaining the sensitivity of traditional polyclonals.

The next generation Multi-rAb secondary antibodies allows our customers to have an exceptionally reliable secondary antibody that works in every application with the same precision and reproducibility from lot to lot.

 

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close